Cargando…
Hypertension and Ischemic Stroke After Aflibercept for Retinopathy of Prematurity
BACKGROUND: Retinopathy of prematurity is the leading cause of preterm infants’ blindness. The preferred method for the management of aggressive posterior ROP is the anti-vascular endothelial growth factor (anti-VEGF). However, systemic and ocular adverse effects of anti-VEGF drugs remain a concern....
Autores principales: | Bazvand, Fatemeh, Khalili pour, Elias, Gharehbaghi, Golnaz, Faghihi, Hooshang, Khodabandeh, Alireza, Mehrabi Bahar, Mohammadreza, Riazi-Esfahani, Hamid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340364/ https://www.ncbi.nlm.nih.gov/pubmed/32694921 http://dx.doi.org/10.2147/IMCRJ.S258881 |
Ejemplares similares
-
Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity
por: Riazi-esfahani, Hamid, et al.
Publicado: (2021) -
Sickle Cell Trait Presenting as Unilateral Proliferative Retinopathy and Macular Thinning in a Pregnant Woman
por: Ghods, Sepideh, et al.
Publicado: (2021) -
Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors
por: Bazvand, Fatemeh, et al.
Publicado: (2021) -
Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020) -
Choroidal features in flat irregular pigment epithelial detachment associated with Chronic central serous chorioretinopathy: Avascular versus vascularized
por: Faghihi, Hooshang, et al.
Publicado: (2021)